Addition of bevacizumab to first-line FOLFOX4 and overall survival in patients with metastatic colorectal cancer.

被引：0
|
作者：
Suenaga, Mitsukuni
Matsusaka, Satoshi
Mizunuma, Nobuyuki
Shinozaki, Eiji
Ogura, Mariko
Ozaka, Masato
Takagi, Koichi
Yamaguchi, Toshiharu
Hatake, Kiyohiko
机构：
[1] Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan
[2] Japanese Fdn Canc Res, Canc Inst Hosp, Clin Chemotherapy, Canc Chemotherapy Ctr,Dept Med Oncol, Tokyo, Japan
[3] Canc Inst Hosp, Tokyo, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 04期
关键词：
D O I：
10.1200/jco.2012.30.4_suppl.610
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
610
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Effect of the addition of bevacizumab to first-line FOLFOX on efficacy, including response rate, progression-free survival, and overall survival, in patients with metastatic colorectal cancer
    Suenaga, M.
    Mizunuma, N.
    Matsusaka, S.
    Shinozaki, E.
    Ogura, M.
    Kuboki, Y.
    Watanabe, T.
    Ozaka, M.
    Chin, K.
    Hatake, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [2] First-line therapy for metastatic colorectal carcinoma: modified FOLFOX4 or FOLFIRI-bevacizumab
    Odabas, H.
    Ozdemir, N.
    Abali, H.
    Oksuzoglu, B.
    Isik, M.
    Uncu, D.
    Cihan, S.
    Seker, M.
    Zengin, N.
    [J]. JOURNAL OF BUON, 2011, 16 (02): : 247 - 252
  • [3] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    [J]. HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [4] Cost comparison of XELOX vs. FOLFOX4 ± bevacizumab as first-line treatment in patients with metastatic colorectal cancer (MCRC):: US findings
    Garrison, L.
    Cassidy, J.
    Saleh, M.
    Lee, F.
    Mena, R.
    Fuloria, J.
    Chang, V
    Ervin, R.
    Stella, P.
    Saltz, L.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : VII74 - VII74
  • [5] Hypertension and survival in unresectable metastatic colorectal cancer (mCRC) patients receiving first-line bevacizumab (BEV) and FOLFOX.
    Burnette, B. L.
    Grothey, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [6] Erlotinib in combination with bevacizumab and FOLFOX4 as second-line chemotherapy for patients with metastatic colorectal cancer
    Shi, Sha
    Lu, Kemei
    Gao, Hui
    Sun, Huidong
    Li, Senlin
    [J]. AMERICAN JOURNAL OF CANCER RESEARCH, 2017, 7 (09): : 1971 - 1977
  • [7] PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS OF METASTATIC COLORECTAL CANCER THERAPY WITH XELOX OR FOLFOX4 WITH OR WITHOUT BEVACIZUMAB AS THE FIRST-LINE TREATMENT
    Tikhomirova, A.
    Kulikov, A.
    Yagudina, R.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A267 - A267
  • [8] Overall survival (OS) analysis from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first-line metastatic colorectal cancer (mCRC)
    Douillard, Jean-Yves
    Siena, Salvatore
    Tabernero, Josep
    Burkes, Ronald L.
    Barugel, Mario Edmundo
    Humblet, Yves
    Bodoky, Gyorgy
    Cunningham, David
    Jassem, Jacek
    Rivera, Fernando
    Kocakova, Ilona
    Ruff, Paul
    Smakal, Martin
    Canon, Jean-Luc
    Rother, Mark
    Oliner, Kelly S.
    Tian, Ying
    Sidhu, Roger
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Retrospective analysis on the efficacy of bevacizumab with FOLFOX as a first-line treatment in Japanese patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ueno, Masashi
    Yamaguchi, Toshiharu
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (04) : 322 - 329
  • [10] Commentary on a phase III trial of bevacizumab plus XELOX or FOLFOX4 for first-line treatment of metastatic colorectal cancer: The NO16966 trial
    Tyagi, Preeta
    Grothey, Axel
    [J]. CLINICAL COLORECTAL CANCER, 2006, 6 (04) : 261 - 264
12345